ESC 365 - GLOBAL LEADERS TRIAL - A randomized comparison of 24 month ticagrelor and 1 month aspirin versus 12 month dual antiplatelet therapy followed by aspirin monotherapy

Back

ESC Premium Access

GLOBAL LEADERS TRIAL - A randomized comparison of 24 month ticagrelor and 1 month aspirin versus 12 month dual antiplatelet therapy followed by aspirin monotherapy

Session: Hot Line Session 3

Topic: Pharmacotherapy

Speaker: Professor P. Serruys (Galway, IE)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Patrick Washington Serruys

National University of Ireland, Galway (Ireland)

19 presentations

3 followers

19 more presentations in this session

Opening question - ATTR-ACT Trial.

Access

Slides

Video

ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Speaker: Professor C. Rapezzi (Ferrara, IT)

Discussant review - ATTR-ACT.

Speaker: Professor J. George (Rehovot, IL)

Access

Slides

Video

Questions from the audience and discussion.

Access

Concluding question - ATTR-ACT Trial.

Access

Slides

Video

Access the full session

Hot Line Session 3

Speakers: Professor P. Serruys, Professor C. Rapezzi, Professor J. George

Access

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

GLOBAL LEADERS TRIAL - A randomized comparison of 24 month ticagrelor and 1 month aspirin versus 12 month dual antiplatelet therapy followed by aspirin monotherapy

About the speaker

Professor Patrick Washington Serruys

19 more presentations in this session

Opening question - ATTR-ACT Trial.

ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Discussant review - ATTR-ACT.

Questions from the audience and discussion.

Concluding question - ATTR-ACT Trial.

Access the full session

Hot Line Session 3

About the event

ESC Congress 2018

ESC 365 is supported by